Posted by Michael Wonder on 16 May 2022
Sun Pharma announces US FDA approval for generic mesalamine extended release capsules
12 May 2022 - Sun Pharmaceutical Industries today announced that it has received final approval from U.S. FDA for its abbreviated new drug application for generic mesalamine 500 mg extended release capsules.
The generic product approval is based on Pentasa 500 mg extended release capsules as a reference product.
